^
Association details:
| Biomarker: | PIK3CA amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EZH2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition
Published date:
10/13/2021
Excerpt:
In this study, we observed that the PIK3CA-mutant or amplified lung cancer cells were more sensitive to EZH2 inhibition....EZH2 inhibitor synergized with PI3K inhibitor in human cancer cells in vitro and worked together efficiently in vivo....This study suggests a promising combination therapy to combat lung cancers with PIK3CA mutation or amplification.
DOI:
10.1016/j.canlet.2021.10.010
